JP7561433B2 - 糖尿病網膜症の予防又は治療薬 - Google Patents

糖尿病網膜症の予防又は治療薬 Download PDF

Info

Publication number
JP7561433B2
JP7561433B2 JP2021522798A JP2021522798A JP7561433B2 JP 7561433 B2 JP7561433 B2 JP 7561433B2 JP 2021522798 A JP2021522798 A JP 2021522798A JP 2021522798 A JP2021522798 A JP 2021522798A JP 7561433 B2 JP7561433 B2 JP 7561433B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antibody
seq
eif5a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522798A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020241660A1 (https=
Inventor
義規 世古
季美枝 村山
務 藤村
貴子 森
明嘉 植村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juntendo University
Original Assignee
Juntendo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juntendo University filed Critical Juntendo University
Publication of JPWO2020241660A1 publication Critical patent/JPWO2020241660A1/ja
Application granted granted Critical
Publication of JP7561433B2 publication Critical patent/JP7561433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021522798A 2019-05-28 2020-05-27 糖尿病網膜症の予防又は治療薬 Active JP7561433B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019099425 2019-05-28
JP2019099425 2019-05-28
PCT/JP2020/020835 WO2020241660A1 (ja) 2019-05-28 2020-05-27 糖尿病網膜症の予防又は治療薬

Publications (2)

Publication Number Publication Date
JPWO2020241660A1 JPWO2020241660A1 (https=) 2020-12-03
JP7561433B2 true JP7561433B2 (ja) 2024-10-04

Family

ID=73553760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522798A Active JP7561433B2 (ja) 2019-05-28 2020-05-27 糖尿病網膜症の予防又は治療薬

Country Status (2)

Country Link
JP (1) JP7561433B2 (https=)
WO (1) WO2020241660A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7729583B2 (ja) * 2021-05-18 2025-08-26 学校法人順天堂 炎症性腸疾患の予防又は治療薬

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007020563A (ja) 2005-06-13 2007-02-01 Sutaagen:Kk 糖尿病網膜症発症及び／又は進展リスクの診断方法
WO2009144933A1 (ja) 2008-05-27 2009-12-03 国立大学法人東京大学 アポトーシス誘導薬
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2016530244A (ja) 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007020563A (ja) 2005-06-13 2007-02-01 Sutaagen:Kk 糖尿病網膜症発症及び／又は進展リスクの診断方法
WO2009144933A1 (ja) 2008-05-27 2009-12-03 国立大学法人東京大学 アポトーシス誘導薬
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2016530244A (ja) 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEKO, Y. et al.，Secreted tyrosine sulfated-eIF5A mediates oxidative stress-induced apoptosis，Scientific Reports，2015年，volume 5, Article number: 13737
SUZUKI, Y. et al.，Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing prot，Graefe's Archive for Clinical and Experimental Ophthalmology，2019年05月06日，volume 257，pages 1519-1525

Also Published As

Publication number Publication date
JPWO2020241660A1 (https=) 2020-12-03
WO2020241660A1 (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
US11440954B2 (en) Optimized anti-TL1A antibodies
US9085617B2 (en) Anti-angiogenic therapy
CN112955464A (zh) 抗pd-1抗体及其用途
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2012515746A (ja) 抗ｃｄ１６０モノクローナル抗体及びその使用
Roque-Navarro et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method
US20260062483A1 (en) Treatment paradigm for an anti-cd19 antibody therapy
JP2026016483A (ja) 抗ヒトｔｌｒ７抗体
WO2023241629A1 (zh) 抗cldn18.2抗体、其药物组合物及用途
JP7561433B2 (ja) 糖尿病網膜症の予防又は治療薬
TW200902063A (en) Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
CN115703835B (zh) 一种抗人crr9单克隆抗体及其制备方法和应用
CN116262787B (zh) 一种抗人lag-3单克隆抗体及其制备方法和应用
JP7729583B2 (ja) 炎症性腸疾患の予防又は治療薬
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
CN115703832B (zh) 具有高阻断活性的抗crr9单克隆抗体及其应用
JP2021155343A (ja) 肺高血圧症の予防又は治療薬
CN110563848A (zh) 一种双特异性抗体及其用途
JP7789368B2 (ja) 炎症性腸疾患に対する治療用抗体
WO2025201517A1 (zh) 抗cd93抗体、其抗原结合片段及其应用
HK40123789A (zh) 优化的抗tl1a抗体
HK1116803B (en) Novel anti-plgf antibody

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230515

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240913

R150 Certificate of patent or registration of utility model

Ref document number: 7561433

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150